Natasha A. Hernday Elected to PDL BioPharma's Board of Directors
Ms. Hernday brings to PDL approximately 25 years of biotechnology experience and currently serves as Senior Vice President, Corporate Development and a member of the Executive Committee of
"Natasha is a seasoned pharmaceutical executive with particular expertise in successfully executing transactions. Her experience with in-licensing, out-licensing and mergers and acquisitions makes her a valuable addition to our Board," said Dr. Selick, Chairman of PDL's Board of Directors. "We look forward to calling on her expertise when reviewing strategic transactions that offer attractive growth potential and compelling financial returns for PDL."
"I'm pleased to join the Board at PDL and to leverage my experience and relationships in advancing the strategy to build a portfolio of actively managed healthcare assets," said Ms. Hernday. "I believe PDL has the resources and expertise to execute strategic transactions that bring value to shareholders, while improving the lives of patients."
During her eight years at
PDL's mission is to improve the lives of patients and create value for our shareholders and our people by applying our capital and expertise for the successful development and commercialization of innovative therapeutics by our partner companies. We deliver on our mission by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential.
View original content to download multimedia:http://www.prnewswire.com/news-releases/natasha-a-hernday-elected-to-pdl-biopharmas-board-of-directors-300873134.html
PDL BioPharma, Inc., Peter Garcia, CFO, 775-832-8500, Peter.firstname.lastname@example.org; LHA Investor Relations, Jody Cain, SVP, 310-691-7100, email@example.com